Illumina, Inc. (ILMN)
ILMN vs. ALNY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?
Why Illumina (ILMN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Illumina Stock Got Mashed on Monday
On Monday, for the second time in as many business days, Illumina (ILMN -5.47%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (^GSPC 0.67%) landed in the black with a 0.7% increase.
Illumina (ILMN) International Revenue Performance Explored
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illumina: Regulatory Risk In China And Weaker Sales Rebound Mask A Solid Rebound Of Its Profitability
Illumina restored its profitability well: Free Cash Flow is reaching elevated levels. However, the placement of ILMN in China's unreliable entity list could have disruptive implications for its operations in the country. The maximum exposure is 7% of its sales, which is manageable.
Why Illumina Stock Is Sinking Today
Shares of Illumina (ILMN -8.97%) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m.
Illumina Analysts Slash Their Forecasts Following Q4 Results
Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday.
ILMN Q4 Earnings Miss Estimates, Stock Dips in Aftermarket
Illumina's fourth-quarter revenues from the consumables business show robust growth.
Illumina, Inc. (ILMN) Q4 2024 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Conor McNamara - RBC Capital Markets Dan Arias - Stifel Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies David Westenberg - Piper Sandler Subha Nambi - Guggenheim Sung Ji Nam - Scotiabank Patrick Donnelly - Citi Operator Good day, ladies and gentlemen and welcome to the Fourth Quarter 2024 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina (ILMN) Q4 Earnings Miss Estimates
Illumina (ILMN) came out with quarterly earnings of $0.86 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.14 per share a year ago.
Illumina forecasts 2025 revenue largely below estimates
Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling subdued demand for its genetic tests and diagnostic tools, sending shares down nearly 4% in extended trading.
